1. Home
  2. BQ vs INDP Comparison

BQ vs INDP Comparison

Compare BQ & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boqii Holding Limited representing

BQ

Boqii Holding Limited representing

HOLD

Current Price

$1.34

Market Cap

6.4M

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.80

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BQ
INDP
Founded
2008
2000
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
5.7M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
BQ
INDP
Price
$1.34
$1.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
122.8K
72.5K
Earning Date
01-05-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$60,004,214.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$1.52
52 Week High
$56.10
$47.60

Technical Indicators

Market Signals
Indicator
BQ
INDP
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
BQ
INDP

About BQ Boqii Holding Limited representing

Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: